AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.
AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.
Funding Rounds (4) - $43.99MUpdate
Current Team (1)Update
|Sep 20, 2016||Business Wire - AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients|
|May 31, 2016||Business Wire - AmpliPhi Biosciences’ CEO to Discuss Novel Approaches to Fighting|
|Jan 28, 2016||PRNewswire UK All - Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies|
|Jan 13, 2016||Bio Portfolio - AmpliPhi Acquires Key Bacteriophage Assets from UK-based Novolytics|
|Jan 8, 2016||Business Wire - AmpliPhi Acquires Key Bacteriophage Assets from UK-based Novolytics|
|Dec 4, 2015||Business Wire - Research and Markets: Global Antibacterial Drugs Market 2015-2019|
|Sep 14, 2015||Business Wire - Research and Markets: Otitis Externa - Global Clinical Trials Review, H2, 2015 Featuring 10 Companies & 8 Top Institutes|
|Aug 18, 2015||Business Wire - AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT|
800 Leigh Street
Richmond, VA 23219